Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide Maintenance in HBV-infected DLBCL After R-CHOP
NCT07493109Phase 3Recruiting
- Start
- May 2026
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tucidinostat in diffuse large B-cell lymphoma (DLBCL) (2 arms). Primary endpoint: Progression-Free Survival at 24 months. Started May 2026; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07493109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07493109.